RUNX2 and breast cancer: CADD522 inhibited the in vitro DNA binding activity of RUNX2 at nanomolar concentrations (IC50 ≅ 10 nM) [53] and inhibited BC growth and metastasis in both in vitro and in vivo models by specifically downregulating RUNX2-mediated transcription of downstream targets [52].